McKesson Raises Full-Year Profit Guidance Following Second Quarter Earnings Beat
McKesson (MCK) has raised its full-year fiscal 2027 adjusted earnings per diluted share guidance following a second-quarter performance that exceeded analyst expectations for both revenue and earnings. The pharmaceutical wholesaler now expects non-GAAP EPS to fall within the range of $45.60 to $46.40, an increase from its previous projection of $44.20 to $45.00. The upward revision places the company's new guidance well above the market consensus of $44.66. This positive momentum reflects strong operational performance within the pharmaceutical distribution sector and provides increased confidence in the company's ability to deliver value throughout the remainder of the fiscal year.
Tickers: $MCK
Topics: earnings beat EPS guidance increase